FAQ Library

Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients.
Dr. Neil Shah discusses the efficacy and safety considerations of the non-kinase inhibitor omacetaxine.
Dr. Neil Shah discusses the efficacy and safety considerations of bosutinib therapy.
Dr. Susan O'Brien discusses the roles of Sokal and Hansford risk calculations in prognosis and treatment.
Dr. Neil Shah discusses the efficacy and safety considerations of dasatinib therapy.
Dr. Jorge Cortes defines chronic-phase CML.
Dr. Susan O'Brien discusses the recommendations for monitoring a mutation analysis in CML.
Dr. Jorge Cortes discusses when you should switch to an alternative TKI.
Dr. Neil Shah discusses the efficacy and safety considerations of nilotinib therapy.
Dr. Susan O'Brien discusses the most recent updates to the NCCN Guidelines for CML.